Incyte | INCY - Operating Expenses


Incyte reported $5.64B in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 270.12M 2.55M Jun/2026
Agenus USD -199.08M 22.15M Jun/2026
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Alnylam Pharmaceuticals USD 1.11B 52.78M Sep/2026
Amgen USD 11.69B 6.9B Jun/2026
BioCryst Pharmaceuticals USD 119.78M 673.63M Jun/2026
Biogen USD 2.32B 663.6M Sep/2026
BioMarin Pharmaceutical USD 6.32B 5.69B Jun/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Eli Lilly USD 10.52B 496M Jun/2026
Exelixis USD 380.28M 20.8M Jun/2026
Gilead Sciences USD 13.04B 9.09B Sep/2026
Incyte USD 5.64B 4.67B Sep/2026
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
MacroGenics USD 42.87M 21.68M Jun/2026
Merck USD 10.75B 5.02B Sep/2026
Moderna USD 960M 817M Jun/2026
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Neurocrine Biosciences USD 739.1M 139.2M Jun/2026
Novartis USD 10.2B 912M Jun/2026
Novartis USD 9.29B 507M Mar/2026
Pfizer USD 85.19B 4.91B Jun/2026
PTC Therapeutics USD 211.54M 15.12M Jun/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Sarepta Therapeutics USD 387.96M 15.59M Jun/2026
Ultragenyx Pharmaceutical USD 289M 16M Jun/2026
Vertex Pharmaceuticals USD 2.07B 217.1M Jun/2026